company background image
ADPT

Adaptive BiotechnologiesNasdaqGS:ADPT Stock Report

Market Cap

US$4.8b

7D

-0.2%

1Y

-34.0%

Updated

26 Oct, 2021

Data

Company Financials +
ADPT fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

ADPT Overview

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases.

Adaptive Biotechnologies Competitors

Thermo Fisher Scientific

NYSE:TMO

US$239.3b

10x Genomics

NasdaqGS:TXG

US$18.4b

AbCellera Biologics

NasdaqGS:ABCL

US$4.3b

NanoString Technologies

NasdaqGM:NSTG

US$2.2b

Price History & Performance

Summary of all time highs, changes and price drops for Adaptive Biotechnologies
Historical stock prices
Current Share PriceUS$33.83
52 Week HighUS$29.74
52 Week LowUS$71.25
Beta0.30
1 Month Change-7.29%
3 Month Change-9.06%
1 Year Change-33.95%
3 Year Changen/a
5 Year Changen/a
Change since IPO-16.06%

Recent News & Updates

Sep 26
Adaptive Biotechnologies (NASDAQ:ADPT) Is In A Good Position To Deliver On Growth Plans

Adaptive Biotechnologies (NASDAQ:ADPT) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

ADPTUS Life SciencesUS Market
7D-0.2%2.7%0.9%
1Y-34.0%36.1%33.4%

Return vs Industry: ADPT underperformed the US Life Sciences industry which returned 36.1% over the past year.

Return vs Market: ADPT underperformed the US Market which returned 33.4% over the past year.

Price Volatility

Is ADPT's price volatile compared to industry and market?
ADPT volatility
ADPT Beta0.30
Industry Beta0.97
Market Beta1

Stable Share Price: ADPT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: ADPT's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2009622Chad Robinshttps://www.adaptivebiotech.com

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines.

Adaptive Biotechnologies Fundamentals Summary

How do Adaptive Biotechnologies's earnings and revenue compare to its market cap?
ADPT fundamental statistics
Market CapUS$4.76b
Earnings (TTM)-US$171.23m
Revenue (TTM)US$133.43m

35.7x

P/S Ratio

-27.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ADPT income statement (TTM)
RevenueUS$133.43m
Cost of RevenueUS$170.75m
Gross Profit-US$37.32m
ExpensesUS$133.92m
Earnings-US$171.23m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

Nov 03, 2021

Earnings per share (EPS)-1.22
Gross Margin-27.97%
Net Profit Margin-128.33%
Debt/Equity Ratio0%

How did ADPT perform over the long term?

See historical performance and comparison

Valuation

Is Adaptive Biotechnologies undervalued compared to its fair value and its price relative to the market?

6.87x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ADPT's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ADPT's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ADPT is unprofitable, so we can't compare its PE Ratio to the US Life Sciences industry average.

PE vs Market: ADPT is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ADPT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ADPT is overvalued based on its PB Ratio (6.9x) compared to the US Life Sciences industry average (6.5x).


Future Growth

How is Adaptive Biotechnologies forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

-2.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ADPT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ADPT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ADPT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ADPT's revenue (25.7% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: ADPT's revenue (25.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ADPT is forecast to be unprofitable in 3 years.


Past Performance

How has Adaptive Biotechnologies performed over the past 5 years?

-44.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ADPT is currently unprofitable.

Growing Profit Margin: ADPT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ADPT is unprofitable, and losses have increased over the past 5 years at a rate of 44.8% per year.

Accelerating Growth: Unable to compare ADPT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ADPT is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (46.6%).


Return on Equity

High ROE: ADPT has a negative Return on Equity (-24.7%), as it is currently unprofitable.


Financial Health

How is Adaptive Biotechnologies's financial position?


Financial Position Analysis

Short Term Liabilities: ADPT's short term assets ($643.7M) exceed its short term liabilities ($116.6M).

Long Term Liabilities: ADPT's short term assets ($643.7M) exceed its long term liabilities ($223.4M).


Debt to Equity History and Analysis

Debt Level: ADPT is debt free.

Reducing Debt: ADPT has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ADPT has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ADPT has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 64.3% each year


Dividend

What is Adaptive Biotechnologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ADPT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ADPT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ADPT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ADPT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ADPT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.7yrs

Average management tenure


CEO

Chad Robins (47 yo)

12.08yrs

Tenure

US$7,131,118

Compensation

Mr. Chad M. Robins, M.B.A., serves as Independent Director at CM Life Sciences III Inc. since April 07, 2021. He serves as an Independent Director at ARYA Sciences Acquisition Corp II since June 2020. He c...


CEO Compensation Analysis

Compensation vs Market: Chad's total compensation ($USD7.13M) is above average for companies of similar size in the US market ($USD5.21M).

Compensation vs Earnings: Chad's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: ADPT's management team is considered experienced (3.7 years average tenure).


Board Members

Experienced Board: ADPT's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: ADPT insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.7%.


Top Shareholders

Company Information

Adaptive Biotechnologies Corporation's employee growth, exchange listings and data sources


Key Information

  • Name: Adaptive Biotechnologies Corporation
  • Ticker: ADPT
  • Exchange: NasdaqGS
  • Founded: 2009
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$4.762b
  • Shares outstanding: 140.77m
  • Website: https://www.adaptivebiotech.com

Number of Employees


Location

  • Adaptive Biotechnologies Corporation
  • 1165 Eastlake Avenue East
  • Suite 200
  • Seattle
  • Washington
  • 98102
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/26 22:40
End of Day Share Price2021/10/26 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.